Parnell Pharm Ord (PARN) 1.62 $PARN Riviera Hir

Parnell Pharm Ord (PARN) 1.62 $PARN

Riviera Hires Tech Entrepreneur Will Hunsinger as COO
GlobeNewswire - Wed Aug 10, 12:00PM CDT
Riviera, a tech-enabled recruiting firm providing services to tech companies seeking the best engineering talent, has announced the appointment of Will Hunsinger as chief operating officer. An experienced entrepreneur who has co-founded and held the title of CEO at several startups, Hunsinger is expressly qualified to assist Riviera with its mission to redefine the recruiting industry using technology and data science.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2016
GlobeNewswire - Thu Aug 04, 6:01AM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced financial results for the first six months of 2016 including; strong revenue growth of 67%; the commencement of contract manufacturing revenues; the upcoming US launch of two new companion animal products, Luminous (TM) and Reviderm(TM); and the commencement of several new studies for PAR121, PAR122 and Zydax for cats.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Contract Manufacturing Agreement with Merial
GlobeNewswire - Tue May 31, 3:05PM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the commencement of a Contract Manufacturing Agreement with Merial, the animal health division of Sanofi.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Pricing of an Underwritten Public Offering of Common Stock
GlobeNewswire - Thu May 12, 6:00AM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQARN), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, today announced the pricing of an underwritten public offering of 2,550,000 of its ordinary shares for $4,207,500. In addition, Parnell has granted the underwriters a 30-day option to purchase, from time to time, in whole or in part, up to an aggregate of 382,500 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 17, 2016, subject to customary closing conditions.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces First Quarter Business Update
GlobeNewswire - Fri Apr 22, 6:00AM CDT
Parnell continues to grow rapidly with revenue increasing 43% for the three months ended March 31, 2016
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings signs USD15m agreement Lincoln Park Captial Fund
M2 - Thu Jan 21, 3:41AM CST
Pharmaceutical company Parnell Pharmaceuticals Holdings (NasdaqGMARN) reported on Wednesday that it has entered into a USD15m share purchase agreement with Lincoln Park CapitalFund.
PARN: 1.62 (+0.08)

UPDATE -- Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Capital Fund to Purchase Ordinary Shares
GlobeNewswire - Wed Jan 20, 12:01PM CST
Parnell Pharmaceuticals Holdings Ltd. ("Parnell" or "Company" (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor ("Lincoln Park". The agreement is structured as an equity commitment and enables Parnell to elect entirely at its discretion to sell up to 35,000 shares on any one day to Lincoln Park and under certain circumstances can elect to sell up to 55,000 shares on any one day.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces Agreement With Lincoln Park Captial Fund to Purchase Ordinary Shares
GlobeNewswire - Tue Jan 19, 4:16PM CST
Parnell Pharmaceuticals Holdings Ltd. ("Parnell" or "Company" (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a share purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor ("Lincoln Park". The agreement is structured as an equity commitment and enables Parnell to elect entirely at its discretion to sell up to 35,000 shares on any one day to Lincoln Park and under certain circumstances can elect to sell up to 55,000 shares on any one day.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Biotech Showcase Conference in San Francisco
GlobeNewswire - Mon Jan 11, 9:02AM CST
Parnell Pharmaceuticals Holdings Ltd (NasdaqARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Biotech Showcase Conference in San Francisco on Monday, January 11, 2015 at 11:30 AM PST.
PARN: 1.62 (+0.08)

Parnell Appoints Ellen B. Richstone and Dr. David K. Rosen to the Board of Directors
GlobeNewswire - Thu Dec 17, 10:00AM CST
Parnell Pharmaceuticals Holdings Ltd (NasdaqARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced the appointment of Ellen B. Richstone and Dr. David K. Rosen to its Board of Directors. The appointments increase the Board to six directors, and the number of independent directors to three.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Jefferies 2015 Global Healthcare Conference in London
GlobeNewswire - Wed Nov 18, 7:00AM CST
Parnell Pharmaceuticals Holdings Ltd (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Jefferies 2015 Global Healthcare Conference in London on Wednesday, November 18, 2015 at 5:20 p.m. GMT.
PARN: 1.62 (+0.08)

Parnell to Report Financial Results for the Nine Months Ended September 30, 2015 on October 21, 2015
GlobeNewswire - Fri Oct 09, 12:00PM CDT
Parnell Pharmaceuticals Holdings Ltd. (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on October 21, 2015 at 7:00 a.m. ET it will report financial results for the nine-month period ended September 30, 2015.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd to Present at Ladenburg Thalmann 2015 Healthcare Conference
GlobeNewswire - Mon Sep 28, 12:54PM CDT
Parnell Pharmaceuticals Holdings Ltd (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that Robert Joseph, President and Chief Executive Officer, will be presenting at the Ladenburg Thalmann 2015 Healthcare Conference in New York on Tuesday, September 29, 2015 at 2:30 PM ET.
PARN: 1.62 (+0.08)

Parnell names Peter A. Croden to board
M2 - Tue Aug 11, 3:16AM CDT
Pharmaceutical company Parnell Pharmaceuticals Holdings (NasdaqGMARN) disclosed on Monday the addition of Peter A. Croden to its board of directors, including its Audit and Compensation Committees.
PARN: 1.62 (+0.08)

Parnell Appoints Peter A. Croden to Board of Directors
GlobeNewswire - Mon Aug 10, 1:00PM CDT
Appointment increases Board to seven members, four of whom are independent
PARN: 1.62 (+0.08)

Parnell to Report Financial Results for the Six Months Ended June 30, 2015 on August 11, 2015
GlobeNewswire - Wed Jul 29, 3:00PM CDT
Parnell Pharmaceuticals Holdings Ltd. (NASDAQARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on August 11, 2015 at 7:00 a.m. ET it will report financial results for the six-month period ended June 30, 2015.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Investor Day Highlights
GlobeNewswire - Thu Jun 18, 10:00AM CDT
Parnell Pharmaceuticals Holdings Ltd (NasdaqARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, released highlights from its inaugural Investor Day held today in New York City. The day was centered on new trial results for Zydax, Parnell's osteoarthritis (OA) therapeutic being developed for dogs and horses, which demonstrated a significant improvement in clinical signs of osteoarthritis in dogs in a pivotal clinical efficacy trial. Management also provided details of its U.S. and European commercialization plans for Zydax and Glyde(R) - Parnell's nutraceutical product for OA. The presentation included guidance for the company's companion and production animal businesses and product pipeline discussion. Noted industry experts provided insights into trends and emerging markets in the animal healthcare industry.
PARN: 1.62 (+0.08)

Parnell Pharmaceuticals Holdings Ltd Announces $11 Million Secured Term Loan Facility
GlobeNewswire - Thu Jun 18, 6:30AM CDT
Parnell Pharmaceuticals Holdings Ltd (NasdaqARN), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, today announced that it has entered into a non-dilutive $US11 million term loan agreement with MidCap Financial. The Company intends to use the loan proceeds for the expansion of its Companion Animal sales team in the US and general company purposes.
PARN: 1.62 (+0.08)